Details of the Drug Combination

General Information of Drug Combination (ID: DC4YGSY)

Drug Combination Name
Acetohexamide Picoplatin
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Acetohexamide   DMR6N7H Picoplatin   DM0PIY6
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 0.52
Bliss Independence Score: 0.52
Loewe Additivity Score: 13.76
LHighest Single Agent (HSA) Score: 13.76

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Acetohexamide
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [2]
Acetohexamide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ATP-binding cassette transporter C8 (ABCC8) TTP835K ABCC8_HUMAN Modulator [4]
------------------------------------------------------------------------------------
Acetohexamide Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [5]
Short-chain dehydrogenase/reductase retSDR1 (DHRS3) DEXPVUN DHRS3_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Acetohexamide Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Albumin (ALB) OTVMM513 ALBU_HUMAN Affects Binding [7]
Carbonyl reductase 3 (CBR3) OT9G6SF0 CBR3_HUMAN Increases ADR [8]
------------------------------------------------------------------------------------
Indication(s) of Picoplatin
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 3 [3]
Ovarian cancer 2C73 Phase 3 [3]
Prostate cancer 2C82.0 Phase 3 [3]
Small-cell lung cancer 2C25.Y Phase 3 [3]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6793).
3 ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
4 Diabetes and insulin secretion: the ATP-sensitive K+ channel (K ATP) connection.Diabetes.2005 Nov;54(11):3065-72.
5 Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
6 Molecular and biochemical characterisation of human short-chain dehydrogenase/reductase member 3 (DHRS3). Chem Biol Interact. 2015 Jun 5;234:178-87.
7 Characterization of the binding of sulfonylurea drugs to HSA by high-performance affinity chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jun 1;878(19):1590-8. doi: 10.1016/j.jchromb.2010.04.019.
8 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.